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First international forum on 
new drugs
Leading European and international experts in the field 
of new psychoactive substances met in Lisbon from  
11–12 May for the First international multidisciplinary 
forum on new drugs (1). Ahead of the event, EMCDDA 
Director Wolfgang Götz referred to the dynamic nature 
of the new drugs phenomenon and the timeliness of an 
event of this kind. ‘The purpose of the forum is to arrive 
at a comprehensive vision for the future regarding how 
these substances will impact on drug use, responses 
and policies’, he said.
The aim of the forum was to take stock of the current 
state of the art in this area and identify common anchor 
points to inform future actions. The programme focused 
on early-warning systems, risk assessments and controls, 
as well as options for prevention and treatment. In 
discussions, the experts traced how this phenomenon 
has developed over the last 10 years and compared, 
through case studies, differing national experiences.  
The 100-strong forum included: forensic scientists; 
epidemiologists; clinicians; law-enforcement experts 
concerned with new drugs; as well as technical staff 
from EU and international institutions.
The forum was organised in conjunction with the 
11th Annual meeting of the EMCDDA–Reitox early-warning 
system (EWS) network. The EWS provides EU Member 
States with an information exchange mechanism for 
reporting on the emergence of new psychoactive 
substances. It is a key element in the European fast-track 
system for assessing and responding to new drugs.
Roumen Sedefov and Ana Gallegos 
New psychoactive substances are becoming widely 
available at an ‘unprecedented pace’. This is 
according to the EMCDDA–Europol 2010 report on 
new drugs entering the European market (1), released 
on 11 May at the Annual meeting of the EMCDDA–
Reitox early-warning system (EWS) network (see 
opposite). Once again, in 2010, a record number of 
new drugs were officially reported to the EMCDDA 
and Europol via the EU early-warning system (EWS) 
on new psychoactive substances. 
According to the report, 41 new psychoactive 
substances were officially notified for the first time to 
the two agencies in 2010. This represents the largest 
number of substances ever reported in a single year, 
considerably up on 2009 (24 substances) and 
2008 (13 substances).
The full list of substances notified, annexed to the 
report, shows a ‘rather diverse’ group, including: 
synthetic cannabinoids, synthetic cathinones, synthetic 
derivatives of well-established drugs as well as one 
plant-based substance (arecoline) (2).
Under the so-called ‘Spice’ phenomenon (3),  
11 new synthetic cannabinoids were picked up in 
2010, bringing the total number of these substances 
monitored by the EWS up to 27. Responding to  
health concerns, at least 16 European countries have 
now taken legal action to ban or otherwise control 
‘Spice’ products and related compounds.
The report gives an account of the risk assessment of 
the synthetic cathinone derivative, mephedrone, which 
led to the decision for Europe-wide controls on the 
drug in December 2010 (4). A further 15 synthetic 
cathinone derivatives were detected during the year. 
Also documented is the first-time appearance of 
derivatives of two established drugs: ketamine and 
PCP (phencyclidine). 
With a large number of new unregulated synthetic 
compounds marketed on the Internet as ‘legal highs’, 
the report describes the EMCDDA’s activities in 
monitoring the online shops selling these substances. 
Commenting on this year’s findings, EMCDDA 
Director Wolfgang Götz said: ‘Given the speed at 
which new developments occur in this area, it is 
important to anticipate future challenges. 
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an ‘unprecedented pace’.
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(1) www.emcdda.europa.eu/events/2011/new-drugs-forum 
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Drug situation
HIV in the European region: unity and diversity
Leading experts in the area of infectious diseases 
will come together in Tallinn from 25–27 May 
for a major European conference: ‘HIV in the 
European region: unity and diversity’ (1). Key 
issues regarding the epidemiology, prevention 
and care of HIV/AIDS in Europe will be debated 
at the event, along with the benefits of regional 
cooperation and networking. The EMCDDA 
takes part in the conference Scientific Board and 
Organising Committees.
The comprehensive programme will cover: 
people living with HIV; local collaboration; 
tuberculosis and HIV; quality of services; HIV in 
prisons; and injecting drug users (IDU). Also high 
on the agenda will be optimising testing and 
earlier care for HIV, a subject taken up in the 
latest edition in the EMCDDA Manuals series: 
Guidelines for testing HIV, viral hepatitis and 
other infections in injecting drug users (2)(3).  
Launched on World AIDS Day 2010, the 
guidelines recommend a strategy to increase the 
uptake of testing for HIV and other infections 
among IDUs. This would enable earlier treatment 
of infected individuals, which would lower the 
risk of infection spreading to the wider population. 
The EMCDDA estimates that 30–50 % of HIV 
positive IDUs in Europe are unaware of being 
infected. The manual provides guidance at a 
practical level, proposing a series of standard 
tests to be undertaken regularly and on a 
voluntary basis. Among these are serology tests 
for HIV, viral hepatitis (A, B, C, D) and other 
sexually transmitted infections; general blood 
tests; and tests for TB. The new guidelines may 
benefit thousands of service providers and 
potentially hundreds of thousands of IDUs in 
Europe and beyond.
(1) The event is organised by the Estonian National Institute 
for Health Development in cooperation with the World 
Health Organization, the United Nations Office on Drugs 
and Crime (UNODC), the Joint United Nations Programme 
on HIV/AIDS (UNAIDS) and other international organisations. 
For more, see www.aids2011.com/en/home
(2) See news release No 14/2010 and www.emcdda.
europa.eu/publications/manuals/testing-guidelines.
(3) Wiessing, L; Blystad, H (2010), ‘EMCDDA publishes 
guidelines on testing for HIV, viral hepatitis and other 
infections in injecting drug users’. Eurosurveillance,  
Volume 15, Issue 48, 2.12.2010. Available online at  
www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19735
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(1) Johnston, L. D., O’Malley, P. M., Bachman, J. G., & 
Schulenberg, J. E. (2011). Monitoring the future. National 
results on adolescent drug use — overview of key findings, 
2010. Ann Arbor: Institute for Social Research,  
The University of Michigan. 
www.monitoringthefuture.org/pubs/monographs/mtf-
overview2010.pdf
Drug trends in Europe often, although not 
always, follow those in the United States, 
albeit with a delay of a few years. For this 
reason, even when there are signs of current 
stabilisation or decline in European drug 
trends, it is important to monitor closely trends 
in the US.
The 2010 ‘Monitoring the future’ study (1) 
— an annual national survey of American 
teenagers, first launched in 1975 — reveals 
that marijuana use continues to rise, in 
contrast to the considerable US decline of the 
preceding decade. On some measures, 
levels of marijuana use are even higher than 
levels of cigarette smoking: 16.7 % of 
10th grade school students (approximately 
aged 15–16) had used marijuana in the past 
month, while only 13.6 % had smoked 
cigarettes. Ecstasy use appears to be making 
Alcohol use among teenagers in 
the US continues its long-term 
decline and reaches historically 
low levels  
a comeback, following a considerable 
decline recently in the belief that its use is 
dangerous. Yet alcohol use, and specifically 
occasions of heavy drinking among 
teenagers, continues its long-term decline, 
reaching historically low levels.
The authors conclude that use of a substance 
is often determined by how the young person 
perceives the benefits and adverse outcomes 
associated with the drug. Unfortunately, 
states the report, word of the supposed 
benefits of using a drug usually spreads more 
rapidly than information about the adverse 
consequences. The EMCDDA will continue to 
monitor the extent to which trends in Europe 
replicate those in the US or follow diverging 
paths.
João Matias and Deborah Olszewski
EMCDDA project explores the importance of ‘survey context’ 
General population surveys are one of the main 
tools for collecting data on drug use in Europe. 
Since the 1990s, every EU Member State has 
conducted at least one, mostly focusing on 
substance use (drug, alcohol and tobacco),  
but sometimes on other topics, such as health 
and healthy lifestyles.
An EMCDDA project, launched in 2010, has 
been investigating the important issue of ‘survey 
context’. Comparing ‘health surveys’ with ‘drug 
surveys’, the project explores the methods used, 
and drug use prevalence estimates resulting 
from, the two contexts. 
The final report of the project, published on the 
EMCDDA website in April (1), reveals that, in 
many countries, health surveys produce lower 
prevalence estimates than specific substance use 
surveys. However, the mechanism of distortion 
remains unclear, as usually there are additional 
differences in survey design (e.g. privacy level, 
interviewer’s level of training, etc.). The report 
provides an overview of possible sources of 
bias and future methodological research needs.
Katerina Skarupova and Deborah Olszewski
(1) ‘Comparison of methods and resulting drug use prevalence 
estimates of health surveys versus drug surveys methods’ at 
www.emcdda.europa.eu/themes/key-indicators/gps
3Responses
Opioid substitution treatment: the role of general 
practitioners 
Mapping ‘drug squads’ in Europe 
European Action on Drugs: 
national event 
General practitioners are becoming an 
increasingly important provider of drug treatment 
services in Europe and are helping to reduce 
inequalities in the accessibility and availability 
of opioid substitution treatment (OST). GPs now 
provide OST to heroin dependent users in  
14 EU countries, usually under shared care 
arrangements with specialised treatment centres. 
It is estimated that around a third of the 
estimated 670 000 clients in OST in Europe 
receive their treatment through GPs. 
While specialist drug treatment services remain 
the EMCDDA’s main data suppliers in this area, 
GPs and other service providers can be a key 
additional information source, helping to 
improve reporting on overall treatment provision 
in Europe. Such information is pivotal in 
assessing the availability and accessibility to 
effective treatment as well as gauging the unmet 
needs of drug users.
Under its 2011 work programme objective  
‘to develop and explore potential new data 
sources on drug treatment and harm reduction’, 
the EMCDDA is investigating strategies for 
collecting treatment data from GPs. It is also 
facilitating the exchange of experience between 
GPs and scientists in the EU regarding the 
benefits of GP involvement in this type of 
treatment (e.g. client health management, 
continuity of care) and the challenges in current 
medical practice (e.g. managing polydrug use, 
diversion of medications) (1).
Alessandro Pirona 
Drug supply reduction is a broad, diverse and 
complex field where drug law enforcement 
plays a central role. In a step towards 
identifying the law-enforcement activities and 
bodies that contribute to reducing drug supply 
in Europe, the EMCDDA has launched a 
mapping project on ‘drug squads’, the units 
specialising in enforcing national drug 
legislation.
‘Improving our knowledge of drug squads in 
the Member States is an essential first step for 
developing our understanding of drug supply 
reduction interventions in Europe’, said 
EMCDDA Director Wolfgang Götz as the 
project kicked off in March. ‘It is a prerequisite 
for the development of drug supply reduction 
indicators’. 
In the period March–May, the EMCDDA drew 
up and tested a questionnaire on drug squads 
which will be used to survey key informants in 
The European Commission and the 
Portuguese NGO Dianova organised in 
Lisbon on 15 March a national event of the 
European Action on Drugs (EAD). 
The EAD is a campaign launched by the 
European Commission on 26 June 2009 to 
mobilise society and raise awareness on the 
dangers of illicit drug use. Building on the 
principle of shared responsibility, the initiative 
encourages individuals and groups to make 
practical commitments to address the drugs 
problem in their daily lives. 
To date, 1 316 EAD commitments have been 
signed (946 of which are online) by 
individuals, celebrities, companies, schools, 
NGOs and other bodies across the 27 EU 
Member States. The EMCDDA was among 
the first organisations signing up to the EAD 
on the day of its launch in 2009.
This, the fifth national EAD event held since 
the campaign began, centered on the 
prevention of drug use and of drug-related 
juvenile delinquency. Six Portuguese EAD 
signatories gave progress reports on how 
they had fulfilled their commitments in 2010, 
while five new signatories described how 
they would do so over the coming year. In 
total there are now 34 commitments signed 
in the country (15 of which are new). 
Chairman of the EMCDDA Management 
Board Dr João Goulão signed a commitment 
in his capacity as President of the Portuguese 
Institute for Drugs and Drug Addiction (IDT). 
Previous EAD national events have been 
organised in Rome (2009) and Berlin, 
London and Warsaw (2010).
the EU Member States (with the support of the 
Reitox network) in June and July. This will lead 
to an overview of the number, institutional 
affiliation and mandate of specialised drug 
squads in Europe. A final report on the project 
is expected in June 2012. 
The EU drugs action plan (2009–12) urges 
more effective law enforcement at EU level to 
counter drug production and trafficking, based 
on an intelligence-led approach. Action 67 of 
the plan calls on the European Commission, 
EMCDDA, Europol and the EU Member States 
to develop key indicators in the area of drug 
supply and drug supply reduction (1).
Rainer Kasecker
(1) ‘European exchange on the practice and current issues 
in opioid substitution treatment in general practitioners’ 
settings’ — www.emcdda.europa.eu/html.cfm/
index2062EN.html
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(1) Action 67: To develop key indicators for the 
collection of policy-relevant data on drug-related crime, 
illegal cultivation, drug markets and supply reduction 
interventions and to develop a strategy to collect them.
For more see http://ec.europa.eu/ead/html/index.jsp
http://ec.europa.eu/ead/docs/leaflets/European%20
Action%20on%20Drugs_Leaflet_LR_EN.pdf
It is estimated that around a  
third of the 670 000 clients in  
opioid substitution treatment in 
Europe receive their treatment  
through GPs
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The use of 
psychoactive 
substances, classified 
by law as ‘narcotics’, 
is an established 
social fact today. 
While this practice 
remains generally recreational and 
occasional, a certain number of consumers 
are regular, and often compulsive, users.
What are the reasons behind the spread of 
drug use since the 1950s?  
How can we understand the behaviour of an 
individual who continues to use drugs when 
he/she would often prefer to give up?  
And what are the social processes and 
policies governing whether a certain 
substance should be classified as a narcotic? 
Sociologie de la drogue, published in French 
in the Repères series, explores the current 
sociological literature to shed light on these 
and other questions relating to drug 
addiction. In four parts, the work explores: 
drugs, culture and society; interdiction, control 
and regulation; drugs, delinquency and 
crime; and the sociology of deviance, drug 
use and addiction.
Author: Henri Bergeron, Scientific coordinator 
of the Health Chair at Sciences Po, Paris, 
researcher at the Centre national de la 
recherche scientifique (CNRS) and member of 
the EMCDDA Scientific Committee.
Publisher: Éditions la découverte, collection 
Repères, No 536. 
Language: French
Price: EUR 9.50 
Date: 2009
ISBN: 978-2-7071-3869-9
Ordering information:  
www.editionsladecouverte.fr/catalogue/
index.php?ean13=9782707138699
The EMCDDA is responsible for the selection 
of materials for the Bookshelf and for the text 
presented. However, responsibility for the content 
of these materials and the opinions expressed 
therein lies with the authors themselves.
Bookshelf
Sociologie de la drogue
INCB launches 2010 Annual report
Feature
Khat use in Europe — implications for European policy 
‘The number of khat users in Europe appears 
to be growing, yet the scale and nature of 
the problem is poorly understood’. This is 
according to the latest EMCDDA publication 
on the issue to be released in June.  
‘Khat use in Europe: implications for European 
policy’ is published in the EMCDDA’s policy 
briefing series Drugs in focus (see page 7) (1). 
Khat (also known as ‘qat’ or ‘chat’) refers to 
the young leaves and shoots of the khat tree 
(Catha edulis), cultivated in the Horn of 
Africa, Southern Arabia and along the East 
African coast. Khat contains stimulant 
substances that have amphetamine-like 
properties (e.g. cathinone) which, in their 
pure forms, are internationally controlled 
substances. The leaves, however, are not 
controlled and no consistent approach exists 
to khat within the EU. 
In Europe, khat is controlled in some, but not 
all, countries and this has resulted in both 
legitimate and criminal transportation 
networks. ‘European khat markets appear to 
be growing but data sources are weak, 
pointing to a need to improve monitoring’, 
states the briefing. 
In Europe, khat is primarily used by migrant 
communities. Despite concern that use 
might diffuse from migrant groups into the 
general population, there is no significant 
evidence that this has occurred. Somatic 
and mental health problems have been 
associated with the excessive use of khat 
and migrant users need to be better 
informed about its potential health, social and 
legal consequences. 
‘Among migrant communities from sub-Saharan 
Africa, khat use is both common and commonly 
overlooked’, says Chairman of the EMCDDA 
Management Board, Dr João Goulão.  
‘We must ensure that people working with these 
communities are aware of the need to identify 
and respond to any negative consequences that 
can result from the use of this substance’.
Over the last three decades, khat has become 
a major source of employment, income and 
revenues in producing countries around the 
Horn of Africa. The most recent data available 
show that khat is treated as an illegal drug in 
15 EU Member States and Norway.
Liesbeth Vandam
(1) Drugs in focus No 21 at www.emcdda.europa.eu/
publications/drugs-in-focus
The 2010 Annual 
report from the 
International 
Narcotics Control 
Board (INCB) was 
launched in 
Vienna on 
2 March.  
This year the 
report highlights 
the role of corruption in drug trafficking 
as well as concerns around designer 
drugs, synthetic cannabinoids and 
precursor chemicals. Also presented  
are regional developments and 
recommendations for governments.  
The INCB issued a special supplement 
to the report on the topic of ensuring 
availability of controlled drugs for 
medical and scientific purposes.  
The report was launched by Professor 
Hamid Ghodse, INCB President.
Report: www.incb.org/pdf/annual-report/2010/en/
AR_2010_English.pdf
Press kit: www.incb.org/pdf/annual-report/2010/
Press_Kit/English/PressKit_english_2010.pdf
Khat users need to be better 
informed about its potential health, 
social and legal consequences
5Drugs-Lex  
Technical expert seminar on ‘threshold quantities’ for drug offences
Countries frequently grade the severity of a 
drug-related offence by assessing the quantity 
of drugs involved in the case. Quantities 
below a certain threshold may lead to one 
level of offence or punishment, while quantities 
above it can lead to harsher consequences. 
The amounts determining the threshold 
between these levels (‘threshold quantities’) 
can vary greatly between nations. 
The issue of ‘threshold quantities’ was explored 
in an international context during an EU-
supported technical expert seminar on the 
issue held in Lisbon in January. Some 20 
experts from five continents attended the event, 
among them members of the judiciary, 
domestic and international policymakers, 
academics and representatives of NGOs.  
The EMCDDA’s 2009 ‘Topic overview on 
threshold quantities’, enriched with 
presentations from other continents, provided a 
solid basis for the discussion (1).
The group agreed that, where threshold 
quantities are used to delimit offences, they 
should be clear and practical both for 
citizens and for the authorities. In order to 
ensure a proportionate outcome,  
they should be non-binding and part of a 
comprehensive package to accommodate 
each circumstance.
Clarifying the aims of established thresholds 
— e.g. achieving public health targets — 
was also considered important. As such aims are 
rarely stated, it is impossible to evaluate their 
‘success’ scientifically and thus difficult to devise 
an ideal system of quantity-setting.
The experts concluded that no single model was 
likely to be appropriate even within the EU. Legal 
systems, police operations and prevalence and 
patterns of drug use vary greatly between 
countries, as do resources and the integrity of the 
institutions and officials overseeing and enforcing 
the schemes. Models should thus be sensitive to 
national contexts and local factors.
Brendan Hughes
Partners Visits
EMCDDA active at CND High-level Polish delegation visits EMCDDA
The Commission on Narcotic Drugs (CND), the central 
UN policymaking body in drug-related matters, held its 
54th session in Vienna from 21–25 March (1). During the 
meeting, which it attended as observer, the EMCDDA 
provided technical support to the European Commission 
and EU Member States, facilitating discussions around 
resolutions on data collection, drugs and driving and 
drug treatment.
This year, the EMCDDA co-organised a side event with 
UNODC and the European Commission entitled  
‘Enhancing cooperation in global data collection  
— the way forward’. This event, which drew around 
50 participants, provided a forum to reflect on the 
opportunities that now exist at global, regional and 
national level to improve capacity to report on the drug 
situation. During the proceedings, the EMCDDA and 
CICAD showcased their joint manual on Building a 
national drugs observatory. UNODC presented a new 
global programme on drug supply and use statistics 
(PROMISE). 
The CND offers the EMCDDA an ideal opportunity to 
present its work to an international audience and to hold 
informal meetings with its partners in Europe and 
worldwide. Held in the margins of this year’s session were 
meetings with UNODC, the WHO and the Canadian 
Centre on Substance Abuse (CSSA).
Klaudia Palczak
(1) For more, see www.emcdda.europa.eu/events/2011/cnd
Under-Secretary of State at the Polish Ministry of Health, Adam Fronczak, headed  
a high-level delegation visiting the EMCDDA in March in the context of the  
upcoming Polish presidency of the EU (1). The purpose of the visit was to present  
the programme of the six-month mandate (July–December), review recent changes  
in Polish drug policy and explore future cooperation and information-exchange  
between the EMCDDA and Polish bodies working in the drugs field.  
Representatives from the European Commission (Directorate-General for Justice)  
also participated.
‘Providing technical advice and support to EU Member States is an important task of 
the EMCDDA’, said EMCDDA Director Wolfgang Götz at the start of the two-day 
visit on 7 March. ‘It is crucial for us to receive feedback on our work directly from 
our stakeholders, such as members of this delegation, in order to better meet their 
needs and expectations’. 
He referred to the ‘very successful cooperation’ between the EMCDDA and Poland 
over the years, characterised by excellent working relations with the Reitox national 
focal point, experts, scientists and regional drug coordinators. 
The work of the EMCDDA and its role as interface between policy and science  
was presented during the visit. Particular attention was paid to the issue of  
psychoactive substances not controlled under drug laws, following a new law  
passed in Poland in 2010 controlling head shops and ‘legal highs’ (2).  
Key drug-related events under the upcoming presidency will include: a drugs and 
driving symposium (17–18 July, Montreal); a conference on cooperation between the 
EU and Eastern Europe/Russia (26–27 October, Warsaw); and a national drug 
coordinators’ meeting (21–22 November, Poznán).
(1) See Fact sheet No 2/2011 at www.emcdda.europa.eu/news/2011/fs-2
(2) See Drugnet Europe 73 for more.
(1) www.emcdda.europa.eu/publications/drugnet/
online/2010/70/article13
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Spotlight
Drug use among the 
prison population
Reitox
IPA project progressing in Bosnia and Herzegovina
Turkish–German twinning project success
The EMCDDA is currently offering technical 
assistance to eight candidate and potential 
candidate countries to the EU under the 
European Commission’s Instrument for  
Pre-accession (IPA) programme (1). The  
EUR 900 000 project, which kicked off in 
April 2010 (IPA3), will run until November 
2011. It is designed to help the eight partners 
establish national drug information systems in 
line with EU standards (2). Important partners in 
the project are ‘Reitox coaches’, representatives 
from EU national focal points (NFP), assigned 
to assist the partners in running national 
activities according to EU norms.
The latest meeting of national stakeholders in 
Bosnia and Herzegovina took place in 
Sarajevo from 22–24 February. This follows 
three previous meetings in the country during 
which an initial work plan was drawn up and 
a national advisory group of seven experts 
established (adopted by the national inter-
ministerial drug commission). This group is 
representative of the complex administrative 
structure of Bosnia and Herzegovina, which 
consists of two entities (the Federation of 
Bosnia and Herzegovina and the Republic of 
Srpska) and one independent district (Brcko). 
It plays a central role in preparing a number 
of the project’s outputs.
At the February meeting, the group and the 
designated ‘Reitox coaches’ reviewed 
progress on the various outputs underway 
including: a data information map; a Country 
overview; and a comprehensive National 
report to the EMCDDA. A national action 
plan for a drug information system is also 
under development, designed to improve 
data availability and fill gaps in existing 
systems. The preparation of these products is 
proceeding according to schedule. Three key 
indicators have been prioritised for 
implementation (treatment demand, drug-
related deaths and general population 
surveys — including the ESPAD survey). 
Synergy between IPA3 project activities and 
ongoing national plans and decision-
making processes will be a key factor in 
contributing to implementation and 
sustainability of project results in Bosnia and 
Herzegovina.
Viktor Mravcik, Alan Lodwick  
(Reitox coaches), Milana Skipina  
(national correspondent)  
and Frédéric Denecker (EMCDDA)
An EU twinning project aimed at strengthening the Turkish Monitoring Centre on Drugs and Drug 
Addiction (TUBIM), was successfully completed in February after a 24-month implementation 
period (1). Turkey’s main partner in the project was the Institute of Therapy Research (IFT) — which 
hosts the German national focal point (NFP) — with the Greek focal point participating as junior 
partner. Other short-term expertise and input was provided by the Czech, French and Polish 
NFPs. The project focused on five components (2). 
As a national centre for drug monitoring, coordination and prevention, TUBIM’s capacity 
increased in many aspects, especially organisational structure. Thanks to the project: media 
awareness was raised; interest of universities in the field was enhanced; TUBIM’s capacity for 
conducting and coordinating scientific studies, data collection and reporting increased; and 
experience during joint activities with EU experts in prevention and treatment was shared.
Frédéric Denecker
(1) http://ec.europa.eu/enlargement/how-does-it-work/
financial-assistance/instrument-pre-accession_en.htm
(2) The eight partners are: Albania, Bosnia-Herzegovina, 
Croatia, the former Yugoslav Republic of Macedonia, 
Kosovo (under UNSCR 1244/99), Montenegro, Serbia 
and Turkey.  
See www.emcdda.europa.eu/publications/drugnet/
online/2010/70/spotlight
(1) The EU twinning programme, launched in 1998, aims to help countries develop modern and efficient administrations 
needed to implement the EU acquis. For more, see: http://ec.europa.eu/enlargement/how-does-it-work/technical-
assistance/twinning_en.htm
(2) See list at www.tubim-twinning.org
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‘Drug use among the prison population: 
scope and responses’, was the focus of the 
latest Reitox Academy held in Lisbon from 
1–2 March. The Academy brought together 
40 experts from across the EU, as well as 
from Croatia, Turkey and international 
organisations. Delegates represented a 
variety of professional backgrounds and 
fields, including prison institutions, health and 
social services (inside and outside prison) 
and drug treatment workers.
High on the agenda was supporting the 
national focal points in writing their national 
contributions to an EMCDDA Selected issue 
publication on prisons, due for release in 
2012. The meeting also provided a platform 
to exchange information on data-collection 
methodologies and the tools available to 
monitor drug use, related problems and 
health responses in prison settings today.
The discussions underlined the increasing 
importance attributed to the issue of drugs 
and prison, both at national and 
international level. In an exchange of 
national experiences, several countries 
confirmed that they had established and 
implemented instruments to collect data and 
information in this environment. Yet data 
collection in prison faces several limitations. 
Major obstacles to collecting valid and 
reliable information include the lack of 
standardised instruments and the issues of 
privacy and fear of control.
As outlined in the 2011 EMCDDA work 
programme, the Academy confirmed the 
need for a more standardised approach to 
data collection in prisons, including European 
standard monitoring tools. The EMCDDA will 
work towards this strategy by involving 
national partners from across Europe. 
Linda Montanari, Ilze Jekabsone  
and Dagmar Hedrich
7The psychoactive plant Salvia divinorum, or the ‘diviner’s sage’, 
is a rare member of the mint family and the latest substance to 
be added to the EMCDDA’s online ‘drug profiles’. Since the 
late 1990s, the use of the plant as a ‘legal’ herbal 
hallucinogen has been increasing, partly due to its availability. 
Smoking the dried and crushed leaves provides short-lived but 
intense hallucinations. The effective dose of salvinorin A, the 
active ingredient of the plant, is comparable to that of the 
synthetic hallucinogens LSD or DOB. This latest addition brings 
the total number of drug profiles up to 18.
Drug profiles, available in German, English and French at  
www.emcdda.europa.eu/publications/drug-profiles
EMCDDA prevention profiles
What are countries in Europe doing to prevent illicit drug use? The EMCDDA’s ‘prevention 
profiles’ aim to answer this question by providing information on the level of implementation 
of different prevention measures in 30 European countries (27 EU Member States, Croatia, 
Turkey and Norway). 
Each ‘prevention profile’ consists of a structured overview of prevention measures in a country, 
according to the four main types of prevention: environmental strategies, universal prevention, 
selective prevention and indicated prevention. In addition, the data can also be displayed on a 
map of Europe which allows the user to examine differences and similarities between countries 
in their implementation of different prevention measures. The profiles, launched in October 2010, 
will undergo a number of updates in May on the basis of new data. In the process, interactive 
elements will be improved and additional information included on family-based prevention.
Available in English at www.emcdda.europa.eu/country-data/prevention/about
Coming soon — General report of activities 2010 
The EMCDDA General report of activities is an annual statutory 
publication providing a detailed progress report of the agency’s 
achievements over a 12-month period. The 2010 edition, due for 
release in June, describes how the EMCDDA implemented its annual 
work programme, highlighting the key activities and accomplishments 
of the year. The results are presented by broad ‘overall objectives’ as 
opposed to ‘individual project goals’. This structure is designed to 
facilitate the cross-checking of results against expected work 
programme outcomes and, in so doing, provide a strong 
management tool for the agency and European institutions alike.
Available in English at www.emcdda.europa.eu/publications/general-report-of-activities
Khat use in Europe: implications for  
European policy
The latest edition in the EMCDDA’s policy briefing series, Drugs in focus, will explore khat use in 
Europe and the implications for European drug policy. The number of khat users in Europe 
appears to be growing, yet the scale and nature of the problem is poorly understood. Research 
studies are therefore required to better assess the market for the drug, evolving patterns of use, 
as well as the extent of any socio-economic and health consequences (see page 4).
Drugs in focus No 21, coming soon in 25 languages at www.emcdda.europa.eu/publications/drugs-in-focus
Resources
Events and 
materials on the 
drugs issue
Eurolib meeting
The EMCDDA plays host on  
19–20 May to the annual 
plenary meeting of Eurolib, 
the organisation of European 
Community and Associated 
libraries. Eurolib aims to: 
promote a wider awareness of the contributions 
made by libraries to the institutions they serve; 
provide a forum for the exchange of professional 
ideas and information; and facilitate the 
development of a common approach to shared 
challenges. Items on the agenda include 
cataloguing electronic documents, grey literature 
and social media.
For more, see www.eurolibnet.eu
International symposium on dismantling 
transnational illicit networks
The European Union and the United States will  
co-host an International symposium on dismantling 
transnational illicit networks from 17–19 May in 
Lisbon. The event is organised by the European 
external action service, in close collaboration with 
the European Commission and the US Department 
of State’s Bureau of International Narcotics and 
Law Enforcement. On 18 May, participants from 
the symposium will visit the EMCDDA. 
For more, see  
http://eeas.europa.eu/us/events/symposium2011/
Symposium: hepatitis care
The 2nd International symposium on hepatitis care 
in substance users will take place from  
15–16 September in Brussels organised by the 
International Network on Hepatitis in Substance 
Users (INHSU). Working sessions will cover: 
organising the management of hepatitis in 
substance users; the treatment of patients in 
prisons; and the virological aspects of infection, 
reinfection and superinfection.  
Deadline for abstracts: 30 June. 
For more, see www.inhsu.com.halito.be/program/
Organisations wishing to publicise their 
newsletters, magazines, websites, CD-ROMs  
or any other resources are invited to contact  
Kathryn.Robertson@emcdda.europa.eu
Products and services
Salvia divinorum — new online drug profile
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EMCDDA meetings
11–12 May:   11th Annual meeting of the Reitox early-
warning system network and First international 
multidisciplinary forum on new drugs, Lisbon.
16–17 May:  EMCDDA Scientific Committee meeting, Lisbon.
18 May:  Executive Committee and Budget 
Committee, Lisbon.
18–20 May:  44th Reitox heads of focal point meeting, Lisbon.
30–31 May:  Expert meeting on the revision of the treatment 
demand indicator, Lisbon.
21–22 June:  Expert meeting on the population surveys 
indicator, Lisbon.
24 June:  EMCDDA celebration of International day 
against drug abuse and illicit trafficking, 
Lisbon.
4 July:   Executive Committee and Budget Committee, 
Lisbon.
4–5 July:   EMCDDA Management Board meeting, Lisbon.
External meetings
17–19 May:  International symposium on dismantling 
transnational illicit networks, Lisbon.
19–20 May:  Eurolib annual plenary meeting, Lisbon.
26 June:  International day against drug abuse and 
illicit drug trafficking (www.un.org/en/events/
drugabuseday/).
17–18 July:  Symposium on drugs and driving, Montreal.
EU meetings
10 May:  Meeting of the national drug coordinators, 
Budapest.
21 June:  Horizontal working party on drugs, Brussels.
27–29 June:  XIII High-level meeting between EU and LAC 
countries, Colombia.
New prize for top scientific papers
EMCDDA to acknowledge excellence in scientific writing 
Europe’s top scientific papers on drug-related topics will be 
acknowledged this year in a new award launched by the EMCDDA on 
its website on 4 March (see Drugnet Europe 73). The prize-giving, to take 
place annually in Lisbon, will celebrate excellence in scientific writing in 
this area of critical concern to EU citizens. 
The inaugural event will take place in the margins of the EMCDDA 
Scientific Committee meeting, being held in the Portuguese capital from 
14–15 November. Articles being judged this year will have been 
published in 2010 in peer-reviewed scientific journals, with the primary 
author based in an EU Member State or Norway. 
Nominations for the award closed on 2 May and the 50 entries will 
now be examined by the jury, composed of members of the Scientific 
Committee and EMCDDA staff. 
Articles eligible for nomination for this annual award focus on illicit 
drugs, although findings on licit substances may also be included. 
Entries are considered in any of the 23 languages of the European 
Union or in Norwegian, along with an abstract in English. 
The importance of scientific publishing has been underlined regularly 
by the EMCDDA Scientific Committee as evidence of scientific 
excellence. The upcoming (non-monetary) prize originated in these 
discussions.
Margareta Nilson
While our early-warning system has recently upped its operational 
capacity to react rapidly to new substances and products identified, it 
currently lacks the ability to anticipate emerging threats. This could be 
addressed by actively purchasing, synthesising and studying new 
compounds and by improving capacity for investigative forensic analysis 
and research at European level’.
Roumen Sedefov and Ana Gallegos
Continued from page 1
Over 40 new drugs reported in 2010
(1) ‘EMCDDA–Europol 2010 annual report on the implementation of Council Decision 
2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances’.  
The report is available at www.emcdda.europa.eu/publications/implementation-reports 
For more on the Council Decision, see www.emcdda.europa.eu/drug-situation/new-drugs 
and www.emcdda.europa.eu/html.cfm/index40105EN.html
(2) See Annex 2.
(3) www.emcdda.europa.eu/publications/thematic-papers/spice
(4) See Risk assessment report at: www.emcdda.europa.eu/publications/risk-assessments
